ArticleThe oncologist2025

Antibody-drug conjugate (disitamab vedotin) therapy targeting HER2-low or higher advanced extramammary Paget's disease.

Sheng Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.